A physiologically-based pharmacokinetic model for the antibiotic ertapenem

Michele L. Joyner; Cammey C. Manning; Whitney  Forbes; Michelle  Maiden; Ariel N.  Nikas; Michele L. Joyner; Cammey C. Manning; Whitney  Forbes; Michelle  Maiden; Ariel N.  Nikas

doi:10.3934/mbe.2016.13.119

Mathematical Biosciences and Engineering

2016, Volume 13, Issue 1: 119-133. doi: 10.3934/mbe.2016.13.119

Previous Article Next Article

A physiologically-based pharmacokinetic model for the antibiotic ertapenem

1.
Department of Mathematics & Statistics, East Tennessee State University, Johnson City, TN, 37614
2.
Department of Mathematics and Computer Science, Meredith College, Raleigh, NC, 27607
3.
Department of Mathematics & Computer Science, Meredith College, Raleigh, NC, 27607

Received: 01 May 2015 Accepted: 29 June 2018 Published: 01 October 2015
MSC : Primary: 92C45; Secondary: 34A35, 65L09.

Ertapenem is an antibiotic commonly used to treat a broad spectrum of infections, which is part of a broader class of antibiotics called carbapenem. Unlike other carbapenems, ertapenem has a longer half-life and thus only has to be administered once a day. A physiologically-based pharmacokinetic (PBPK) model was developed to investigate the uptake, distribution, and elimination of ertapenem following a single one gram dose. PBPK modeling incorporates known physiological parameters such as body weight, organ volumes, and blood flow rates in particular tissues. Furthermore, ertapenem is highly bound in human blood plasma; therefore, nonlinear binding is incorporated in the model since only the free portion of the drug can saturate tissues and, hence, is the only portion of the drug considered to be medicinally effective. Parameters in the model were estimated using a least squares inverse problem formulation with published data for blood concentrations of ertapenem for normal height, normal weight males. Finally, an uncertainty analysis of the parameter estimation and model predictions is presented.

Keywords:

Ertapenem,
physiologically based pharmacokinetic model (PBPK),
free concentration,
ordinary differentialequations.,
bound concentration

Citation: Michele L. Joyner, Cammey C. Manning, Whitney Forbes, Michelle Maiden, Ariel N. Nikas. A physiologically-based pharmacokinetic model for the antibiotic ertapenem[J]. Mathematical Biosciences and Engineering, 2016, 13(1): 119-133. doi: 10.3934/mbe.2016.13.119

Related Papers:

[1]	Michele L. Joyner, Cammey Cole Manning, Whitney Forbes, Valerie Bobola, William Frazier . Modeling Ertapenem: the impact of body mass index on distribution of the antibiotic in the body. Mathematical Biosciences and Engineering, 2019, 16(2): 713-726. doi: 10.3934/mbe.2019034
[2]	Colette Calmelet, John Hotchkiss, Philip Crooke . A mathematical model for antibiotic control of bacteria in peritoneal dialysis associated peritonitis. Mathematical Biosciences and Engineering, 2014, 11(6): 1449-1464. doi: 10.3934/mbe.2014.11.1449
[3]	Eric Salgado, Yanguang Cao . Pharmacokinetics and pharmacodynamics of therapeutic antibodies in tumors and tumor-draining lymph nodes. Mathematical Biosciences and Engineering, 2021, 18(1): 112-131. doi: 10.3934/mbe.2021006
[4]	Rebeccah E. Marsh, Jack A. Tuszyński, Michael Sawyer, Kenneth J. E. Vos . A model of competing saturable kinetic processes with application to the pharmacokinetics of the anticancer drug paclitaxel. Mathematical Biosciences and Engineering, 2011, 8(2): 325-354. doi: 10.3934/mbe.2011.8.325
[5]	Urszula Ledzewicz, Heinz Schättler . The Influence of PK/PD on the Structure of Optimal Controls in Cancer Chemotherapy Models. Mathematical Biosciences and Engineering, 2005, 2(3): 561-578. doi: 10.3934/mbe.2005.2.561
[6]	Jiaxu Li, Yang Kuang . Systemically modeling the dynamics of plasma insulin in subcutaneous injection of insulin analogues for type 1 diabetes. Mathematical Biosciences and Engineering, 2009, 6(1): 41-58. doi: 10.3934/mbe.2009.6.41
[7]	Zheng Dai, I.G. Rosen, Chuming Wang, Nancy Barnett, Susan E. Luczak . Using drinking data and pharmacokinetic modeling to calibrate transport model and blind deconvolution based data analysis software for transdermal alcohol biosensors. Mathematical Biosciences and Engineering, 2016, 13(5): 911-934. doi: 10.3934/mbe.2016023
[8]	Norbert Hungerbühler . Optimal control in pharmacokinetic drug administration. Mathematical Biosciences and Engineering, 2022, 19(5): 5312-5328. doi: 10.3934/mbe.2022249
[9]	Jifa Jiang, Qiang Liu, Lei Niu . Theoretical investigation on models of circadian rhythms based on dimerization and proteolysis of PER and TIM. Mathematical Biosciences and Engineering, 2017, 14(5&6): 1247-1259. doi: 10.3934/mbe.2017064
[10]	Kun Zheng, Junjie Shen, Guangmin Sun, Hui Li, Yu Li . Shielding facial physiological information in video. Mathematical Biosciences and Engineering, 2022, 19(5): 5153-5168. doi: 10.3934/mbe.2022241

Abstract

References

[1]	CRC Press, Boca Raton, Fl, 2014.
[2]	Comput. Meth. Prog. Bio., 88 (2007), 52-61.
[3]	in Preclinical Development Handbook: ADME Biopharmaceutical Properties (ed. S. C. Gad), Wiley-Interscience, John Wiley & Sons, Inc., 2008, 1167-1127.
[4]	Am. J. Physiol. - Reg. I., 239 (1980), R7-R24.
[5]	Circulation, 95 (1997), 1837-1843.
[6]	http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=150610#x27.
[7]	Antimicrob. Agents Chemother., 54 (2010), 924-926.
[8]	Antimicrob. Agents Ch., 45 (2001), 1915-1918.
[9]	International Life Sciences Institute, Risk Sciences Institute, 1994.
[10]	Invanz® (ertapenem for injection), 2012.
[11]	Journal of Clinical Pharmacology, 29 (1989), 488-493.
[12]	Drugs, 65 (2005), 2151-2178.
[13]	Am. J. Clin. Nutr., 48 (1988), 1351-1361.
[14]	J. Antimicrob. Chemoth., 52 (2003), 331-344.
[15]	American Society for Microbiology, 46 (2002), 3506-3511.
[16]	The MathWorks Inc., Natick, Massachusetts, 2011.
[17]	J. Antimicrob. Chemoth., 53 (2004), ii23-ii28.
[18]	J. Pharmacokinet. Phar., 37 (2010), 365-405.
[19]	Toxicol. Sci., 69 (2002), 60-78.
[20]	J. Toxicol. Env. Health, 46 (1995), 117-129.
[21]	Human and Experimental Toxicology, 14 (1995), 273-280.
[22]	Crit. Rev. Toxicol., 33 (2003), 469-503.
[23]	J. Antimicrob. Chemoth., 52 (2003), 538-542.
[24]	http://datathief.org/.
[25]	Metabolis., 55 (2006), 515-524.

This article has been cited by:

1.	Lingling Ye, Meng Ke, Xiang You, Pinfang Huang, Cuihong Lin, A Physiologically Based Pharmacokinetic Model of Ertapenem in Pediatric Patients With Renal Impairment, 2020, 109, 00223549, 2909, 10.1016/j.xphs.2020.06.010
2.	Tetsushu Onita, Noriyuki Ishihara, Takahisa Yano, PK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance, 2025, 14, 2079-6382, 92, 10.3390/antibiotics14010092

Reader Comments

Your name:*

Email:*
© 2016 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)